share_log

雲頂新耀-B:自願公告 最新業務情況 有關耐賦康用於治療成人患者具有進展風險的原發性IgA腎病的新藥上市申請在中國獲批

EVEREST MED-B: VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE APPROVAL OF NEW DRUG APPLICATION IN CHINA FOR NEFECON FOR THE TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY IN ADULTS AT RISK OF DISEASE PROGRESSION

香港交易所 ·  Nov 23, 2023 23:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more